| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000005959 |
| Receipt No. | R000007018 |
| Scientific Title | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication |
| Date of disclosure of the study information | 2011/07/12 |
| Last modified on | 2019/08/06 (Ver. 2) |
| Basic information | ||
| Public title | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication | |
| Acronym | Clinical study on therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | |
| Scientific Title | Prospective clinical study of the therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans showing intermittent claudication | |
| Scientific Title:Acronym | Clinical study on therapeutic effects of prostaglandin in patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | |
| Region |
|
|
| Condition | ||
| Condition | Patients with combined lumbar spinal stenosis and arteriosclerosis obliterans | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The prospective study is performed with the aim to evaluate the therapeutic effects of prostaglandin from the viewpoint of administration method and duration by administering the drug to patients with combined lumbar spinal stenosis and arteriosclerosis obliterans (peripheral arterial disease) who exhibit intermittent claudication, which tends to increase in aging society. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | The Japanese Orthopaedic Association (JOA) score |
| Key secondary outcomes | Age, sex, affected period, biochemical examination of blood, details of treatment (number and frequency of infusions, concomitant drug therapy, block therapy, and other conservative therapies), SF-36, VAS |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 3 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Prostaglandin for injection (alprostadil) group: 60 mcg of prostaglandin for injection is intravenously administered once a week or more. This therapy is repeated 10 times or more. | |
| Interventions/Control_2 | Ripple injection (alprostadil Injection) group: 10 mcg of ripple injection is administered intravenously once a week or more. This treatment is repeated 10 times or more. | |
| Interventions/Control_3 | Conventional treatment group | |
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | The subjects are patients who meet all of the following inclusion criteria and are able to provide informed consent.
1) Male and female patients aged 20 years or older. 2) Patients who are diagnosed with lumbar spinal stenosis based on X-ray and MRI findings and are undergoing conservative treatment. 3) Patients who are diagnosed with arteriosclerosis obliterans (peripheral arterial disease) Fontaine classification I or II. 4) Patients who understand the objectives of this study and provide informed consent. |
|||
| Key exclusion criteria | The patients who meet any of the following exclusion criteria are excluded.
1) Patients who have ethical difficulties due to special consideration required for them or their family. 2) Patients with diabetes, chronic renal failure, etc. who are suspected to have a complication of peripheral nerve disorder or circulatory disorder. 3) Patients who are receiving administration of anticoagulant, etc. 4) Patients who have a history of surgical treatment for the spine/spinal cord. 5) Patients who have problematic infection. 6) Patients who do not understand the objectives of this study. |
|||
| Target sample size | 300 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Tokai University School of Medicine | ||||||
| Division name | Department of Orthopaedic Surgery | ||||||
| Zip code | |||||||
| Address | 143,Shimokasuya,Isehara,Kanagawa,259-1193,Japan | ||||||
| TEL | 0463-93-1121 | ||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Tokai University School of Medicine | ||||||
| Division name | Department of Orthopaedic Surgery | ||||||
| Zip code | |||||||
| Address | 143,Shimokasuya,Isehara,Kanagawa,259-1193,Japan | ||||||
| TEL | 0463-93-1121 | ||||||
| Homepage URL | |||||||
| Sponsor | |
| Institute | Tokai University Hospital
Department of Orthopaedic Surgery |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Tokai University Hospital
Department of Orthopaedic Surgery |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007018 |